Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising combo tackles myeloma, but not a cure

NCT ID NCT02441686

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 36 times

Summary

This study tested a combination of three drugs (lenalidomide, bortezomib, and dexamethasone) in 46 people newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how well the treatment controlled the disease and what side effects occurred. While many patients responded, this approach manages the cancer rather than eliminating it, and ongoing treatment is typically needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Eastern Maine Medical Center

    Brewer, Maine, 04412, United States

  • Hematology Oncology of Northern New Jersey

    Morristown, New Jersey, 07962, United States

  • Massachusetts General Hosptial

    Boston, Massachusetts, 02114, United States

  • Virgina Piper Cancer Institute

    Minneapolis, Minnesota, 55407, United States

  • Virginia Piper Cancer Institute

    Coon Rapids, Minnesota, 55433, United States

Conditions

Explore the condition pages connected to this study.